Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide

Journal of Endocrinology

Volumn 203, Issue 3, 2009, Pages 375-387

  Langenheim, John F ^a,b   Chen, Wen Y ^a,b  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE ANTAGONIST; HORMONE ANTAGONIST GLUTAMINYLARGINYLLEUCYLISOLEUCYLGLUTAMYLASPARTYLISOLEUCYLCYSTYLLEUCYLPROLYLARGINYLTRYPTOPHANYLGLYCYLCYSTYLLEUCYLTRYPTOPHANYLGLUTAMYLASPARTYLASPARTYLPHENYLALANYL CONJUGATE; HUMAN GROWTH HORMONE; HUMAN GROWTH HORMONE LUTAMINYLARGINYLLEUCYLISOLEUCYLGLUTAMYLASPARTYLISOLEUCYLCYSTYLLEUCYLPROLYLARGINYLTRYPTOPHANYLGLYCYLCYSTYLLEUCYLTRYPTOPHANYLGLUTAMYLASPARTYLASPARTYLPHENYLALANINE CONJUGATE; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROLACTIN; PROLACTIN GLUTAMINYLARGINYLLEUCYLISOLEUCYLGLUTAMYLASPARTYLISOLEUCYLCYSTYLLEUCYLPROLYLARGINYLTRYPTOPHANYLGLYCYLCYSTYLLEUCYLTRYPTOPHANYLGLUTAMYLASPARTYLASPARTYLPHENYLALANINE CONJUGATE; RECOMBINANT HORMONE; STAT5 PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BREAST DEVELOPMENT; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAMMARY GLAND; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT GAIN;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; JANUS KINASE 2; MAMMARY GLANDS, ANIMAL; MAP KINASE SIGNALING SYSTEM; MICE; PROLACTIN; RATS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; STAT5 TRANSCRIPTION FACTOR;

EID: 71949120963     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-09-0211     Document Type: Article

References (74)

1. Beck MT, Chen NY, Franek KJ & Chen WY 2003 Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Research 63 3598-3604.
2. Bravo G, Zazueta B & Lavalle C 1992 An acute remission of Reiter's syndrome in male patients treated with bromocriptine. Journal of Rheumatology 19 747-750.
3. Brodbeck KJ, Pushpala S & McHugh AJ 1999 Sustained release of human growth hormone from PLGA solution depots. Pharmaceutical Research 16 1825-1829. (Pubitemid 30040697)
4. Carlo-Stella C, Di Nicola M, Milani R, Longoni P, Milanesi M, Bifulco C, Stucchi C, Guidetti A, Cleris L, Formelli F et al. 2004 Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone. Experimental Hematology 32 171-178. (Pubitemid 38180563)
5. Chen WY, Wight DC, Wagner TE & Kopchick JJ 1990 Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. PNAS 87 5061-5065. (Pubitemid 20224272)
6. Chen WY, White ME, Wagner TE & Kopchick JJ 1991a Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology 129 1402-1408.
7. Chen WY, Wight DC, Chen NY, Coleman TA, Wagner TE & Kopchick JJ 1991b Mutations in the third alpha-helix of bovine growth hormone dramatically affect its intracellular distribution in vitro and growth enhancement in transgenic mice. Journal of Biological Chemistry 266 2252-2258.
8. Chen WY, Wight DC, Mehta BV, Wagner TE & Kopchick JJ 1991c Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Molecular Endocrinology 5 1845-1852.
9. Chen WY, Chen NY, Yun J, Wagner TE & Kopchick JJ 1994 In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. Journal of Biological Chemistry 269 15892-15897.
10. Chen WY, Chen NY, Yun J, Wight DC, Wang XZ, Wagner TE & Kopchick JJ 1995 Amino acid residues in the third alpha-helix of growth hormone involved in growth promoting activity. Molecular Endocrinology 9 292-302.
11. Chen WY, Ramamoorthy P, Chen N, Sticca R &Wagner TE 1999 A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clinical Cancer Research 5 3583-3593.
12. Chen NY, Holle L, Li W, Peirce SK, Beck MT & Chen WY 2002 In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. International Journal of Oncology 20 813-818.
13. Chen BJ, Cui X, Sempowski GD & Chao NJ 2003 Growth hormone accelerates immune recovery following allogeneic T-cell-depleted bone marrow transplantation in mice. Experimental Hematology 31 953-958. (Pubitemid 37211380)
14. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima G, Chang S, Chu H, Mukku V, Canova-Davis E et al. 1996 Long-acting growth hormones produced by conjugation with polyethylene glycol. Journal of Biological Chemistry 271 21969-21977. (Pubitemid 26303822)
15. Cook DM, Biller BM, Vance ML, Hoffman AR, Phillips LS, Ford KM, Benziger DP, Illeperuma A, Blethen SL, Attie KM et al. 2002 The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 87 4508-4514. (Pubitemid 35251858)
16. Cox GN, Rosendahl MS, Chlipala EA, Smith DJ, Carlson SJ & Doherty DH 2007 A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats. Endocrinology 148 1590-1597.
17. Cunningham BC & Wells JA 1991 Rational design of receptor-specific variants of human growth hormone. PNAS 88 3407-3411.
18. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D & Damico LA 2002 Albumin binding as a general strategy for improving the pharmacokinetics of proteins. Journal of Biological Chemistry 277 35035-35043. (Pubitemid 35052399)
19. Dugan AL, Thellin O, Buckley DJ, Buckley AR, Ogle CK & Horseman ND 2002 Effects of prolactin deficiency on myelopoiesis and splenic T lymphocyte proliferation in thermally injured mice. Endocrinology 143 4147-4151. (Pubitemid 35244396)
20. Figueroa FE, Carrion F, Martinez ME, Rivero S & Mamani I 1997 Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis. British Journal of Rheumatology 36 1022-1023. (Pubitemid 27450082)
21. Fuh G &Wells JA 1995 Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. Journal of Biological Chemistry 270 13133-13137.
22. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV & Wells JA 1992 Rational design of potent antagonists to the human growth hormone receptor. Science 256 1677-1680.
23. Fuh G, Colosi P, Wood WI & Wells JA 1993 Mechanism-based design of prolactin receptor antagonists. Journal of Biological Chemistry 268 5376-5381. (Pubitemid 23090852)
24. Goffin V, Struman I, Goormaghtigh E & Martial JA 1993 The addition of nine residues at the C-terminus of human prolactin drastically alters its biological properties. European Journal of Biochemistry 214 483-490. (Pubitemid 23173799)
25. Goffin V, Struman I, Mainfroid V, Kinet S & Martial JA 1994 Evidence for a second receptor binding site on human prolactin. Journal of Biological Chemistry 269 32598-32606.
26. Goffin V, Kinet S, Ferrag F, Binart N, Martial JA & Kelly PA 1996 Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. Journal of Biological Chemistry 271 16573-16579. (Pubitemid 26239012)
27. Gunn AJ, Gunn TR, Rabone DL, Breier BH, Blum WF & Gluckman PD 1996 Growth hormone increases breast milk volumes in mothers of preterm infants. Pediatrics 98 279-282.
28. Hanley MB, Napolitano LA & McCune JM 2005 Growth hormone-induced stimulation of multilineage human hematopoiesis. Stem Cells 23 1170-1179. (Pubitemid 41377732)
29. Hardin DS, Kemp SF & Allen DB 2007 Twenty years of recombinant human growth hormone in children: relevance to pediatric care providers. Clinical Pediatrics 46 279-286.
30. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND & Tomlinson IM 2008 Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Engineering, Design & Selection 21 283-288.
31. Hovey RC, Asai-Sato M, Warri A, Terry-Koroma B, Colyn N, Ginsburg E & Vonderhaar BK 2005 Effects of neonatal exposure to diethylstilbestrol, tamoxifen, and toremifene on the BALB/c mouse mammary gland. Biology of Reproduction 72 423-435. (Pubitemid 40129719)
32. Howell SJ, Anderson E, Hunter T, Farnie G & Clarke RB 2008 Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Research 10 R68.
33. Ip MM & Asch BB 2000 Methods in Mammary Gland Biology and Breast Cancer Research., New York: Kluwer Academic/Plenum Publishers.
34. Jacobs JW, Qin S, Zhang M, Li H & Park M-O 2006 Human Growth Hormone Conjugated with Biocompatible Polymer. United States Patent Application 20060134736.
35. Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, Shepard D, Shahzamani A, Jones AJ & Putney SD 1996 A month-long effect from a single injection of microencapsulated human growth hormone. Nature Medicine 2 795-799. (Pubitemid 26225096)
36. Jostel A, Mukherjee A, Alenfall J, Smethurst L & Shalet SM 2005 A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. Clinical Endocrinology 62 623-627. (Pubitemid 40646733)
37. Kastrup KW, Christiansen JS, Andersen JK & Orskov H 1983 Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinologica 104 148-152.
38. Langenheim JF & Chen WY 2005 Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A. Breast Cancer Research and Treatment 90 281-293.
39. Langenheim JF, Tan D, Walker AM & Chen WY 2006 Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. Molecular Endocrinology 20 661-674. (Pubitemid 43291216)
40. MacGillivray MH, Baptista J & Johanson A 1996 Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group. Journal of Clinical Endocrinology and Metabolism 81 1806-1809. (Pubitemid 26152468)
41. Majumder B, Biswas R & Chattopadhyay U 2002 Prolactin regulates antitumor immune response through induction of tumoricidal macrophages and release of IL-12. International Journal of Cancer 97 493-500. (Pubitemid 34027809)
42. Martinez-Gomez MA, Sagrado S, Villanueva-Camanas RM & Medina-Hernandez MJ 2006 Characterization of basic drug-human serum protein interactions by capillary electrophoresis. Electrophoresis 27 3410-3419. (Pubitemid 44430721)
43. McMurray RW, Weidensaul D, Allen SH & Walker SE 1995 Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. Journal of Rheumatology 22 2084-2091.
44. Meli R, Raso GM, Bentivoglio C, Nuzzo I, Galdiero M & Di Carlo R 1996 Recombinant human prolactin induces protection against Salmonella typhimurium infection in the mouse: role of nitric oxide. Immunopharmacology 34 1-7. (Pubitemid 26284172)
45. Milsom SR, Rabone DL, Gunn AJ & Gluckman PD 1998 Potential role for growth hormone in human lactation insufficiency. Hormone Research 50 147-150. (Pubitemid 28472842)
46. Muller AF, Janssen JA, de Herder WW & van der Lely AJ 2001 Growth hormone receptor antagonists: potential indications. Nederlands Tijdschrift Voor Geneeskunde 145 69-73. (Pubitemid 32057736)
47. Oberholtzer E, Contarini M, Veglia F, Cossarizza A, Franceschi C, Geuna M, Provinciali M, Di Stefano G, Sissom J, Brizzi MF et al. 1996 Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors. Advances in Neuroimmunology 6 233-247. (Pubitemid 26412644)
48. Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL & Parry TJ 2002 Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. European Journal of Pharmacology 456 149-158. (Pubitemid 35351748)
49. Page-Wilson G, Smith PC & Welt CK 2007 Short-term prolactin administration causes expressible galactorrhea but does not affect bone turnover: pilot data for a new lactation agent. International Breastfeeding Journal 2 10.
50. Peeva E, Venkatesh J, Michael D & Diamond B 2004 Prolactin as a modulator of B cell function: implications for SLE. Biomedicine and Pharmacotherapy 58 310-319. (Pubitemid 38759730)
51. Ramamoorthy P, Sticca R, Wagner TE & Chen WY 2001 In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. International Journal of Oncology 18 25-32.
52. Reiter EO, Attie KM, Moshang T Jr, Silverman BL, Kemp SF, Neuwirth RB, Ford KM & Saenger P 2001 A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. Journal of Clinical Endocrinology and Metabolism 86 4700-4706. (Pubitemid 33020508)
53. Reynolds C, Montone KT, Powell CM, Tomaszewski JE & Clevenger CV 1997 Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 138 5555-5560. (Pubitemid 27509722)
54. Richards SM & Murphy WJ 2000 Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. Journal of Neuroimmunology 109 56-62.
55. Richards SM, Garman RD, Keyes L, Kavanagh B & McPherson JM 1998 Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas. Cellular Immunology 184 85-91. (Pubitemid 28265565)
56. Rosen CA & HaseltineWA 2006 Albumin Fusion Proteins. United States Patent 699485. Human Genome Sciences, Inc, Rockville, MD, USA.
57. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ & Ho KK 2001 Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. Journal of Clinical Endocrinology and Metabolism 86 1716-1723. (Pubitemid 32374928)
58. Scotti ML, Langenheim JF, Tomblyn S, Springs AE & Chen WY 2008 Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Research and Treatment 111 241-250.
59. SomersW, Ultsch M, De Vos AM & Kossiakoff AA 1994 The X-ray structure of a growth hormone-prolactin receptor complex. Nature 372 478-481. (Pubitemid 24987320)
60. Sun R, Gault RA, Welniak LA, Tian ZG, Richards S & Murphy WJ 2003 Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice. Biology of Blood and Marrow Transplantation 9 426-434. (Pubitemid 38351800)
61. Sun R, Zhang J, Zhang C, Zhang J, Liang S, Sun A, Wang J & Tian Z 2004 Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice. Cellular & Molecular Immunology 1 129-136.
62. Tae G, Kornfield JA & Hubbell JA 2005 Sustained release of human growth hormone from in situ forming hydrogels using self-assembly of fluoroalkyl-ended poly(ethylene glycol). Biomaterials 26 5259-5266. (Pubitemid 40387848)
63. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC & Bennett WF 1999 Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. Journal of Clinical Endocrinology and Metabolism 84 2098-2103. (Pubitemid 30647040)
64. Tomblyn S, Langenheim JF, Jacquemart IC, Holle E & Chen WY 2005 The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. International Journal of Oncology 27 1381-1389.
65. Tracy MA 1998 Development and scale-up of a microsphere protein delivery system. Biotechnology Progress 14 108-115. (Pubitemid 28118271)
66. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML et al. 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 342 1171-1177. (Pubitemid 30211048)
67. Ultsch MH, Somers W, Kossiakoff AA & de Vos AM 1994 The crystal structure of affinity-matured human growth hormone at 2 A resolution. Journal of Molecular Biology 236 286-299. (Pubitemid 124001366)
68. Webster R, Xie R, Didier E, Finn R, Finnessy J, Edgington A & Walker D 2008 PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. Xenobiotica 38 1340-1351.
69. Woody MA, Welniak LA, Richards S, Taub DD, Tian Z, Sun R, Longo DL & Murphy WJ 1999a Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation. Neuroimmunomodulation 6 69-80. (Pubitemid 29049160)
70. Woody MA, Welniak LA, Sun R, Tian ZG, Henry M, Richards S, Raziuddin A, Longo DL & Murphy WJ 1999b Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine. Experimental Hematology 27 811-816. (Pubitemid 29231018)
71. Zhang G, Li W, Holle L, Chen N & Chen WY 2002 A novel design of targeted endocrine and cytokine therapy for breast cancer. Clinical Cancer Research 8 1196-1205. (Pubitemid 35177375)
72. Zhang J, Sun R, Wei H & Tian Z 2005a Antitumor effects of recombinant human prolactin in human adenocarcinoma-bearing SCID mice with human NK cell xenograft. International Immunopharmacology 5 417-425. (Pubitemid 40126364)
73. Zhang WC, Sun R, Zhang J, Zhang J & Tian Z 2005b Recombinant human prolactin protects against irradiation-induced myelosuppression. Cellular & Molecular Immunology 2 379-385.
74. Zhang J, Sun R & Tian Z 2007 Human prolactin promotes human secondary immunoglobulin response in human/SCID mouse chimeras. Clinical and Vaccine Immunology 14 60-64.